There is one thing in the wording that is striking me now on the Iomab-B PhIII trial.
I thought initially they had missed a comma between "early termination" and "for futility" as in the previous PRs like this one from April: "Actinium plans to exercise an ad-hoc analysis that could generate topline data for the primary endpoint in late 2020 and early termination of the trial if positive".
Does someone know where this has gone ?
Another thing unknown in my vocabulary is "futility in the control arm" from the 10Q.
By definition, control arm being control, futility (if demonstrated) should be shown in the test arm vs the control. I do not fully comprehend this wording.
One interpretation could be that they failed significance in this interim and are waiting for further analysis to determine whether they do have enough eligible patients in the control arm.
Does someone read like me ?
News 
Market Data 
Discover 
